Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma

• Published in: Journal of neuro-oncology 2022-02, Vol.156 (3), p.499-507
• Main Authors: Park, Deborah Y., Tom, Martin C., Wei, Wei, Tewari, Surabhi, Ahluwalia, Manmeet S., Yu, Jennifer S., Chao, Samuel T., Suh, John H., Peereboom, David, Stevens, Glen H. J., Barnett, Gene H., Angelov, Lilyana, Mohammadi, Alireza M., Hogan, Thomas, Kissel, Courtney, Lapin, Brittany, Schuermeyer, Isabel, Parsons, Michael W., Naugle, Richard, Murphy, Erin S.
• Format: Article
• Language: English
• Subjects: Adult; Brain cancer; Brain Neoplasms - pathology; Brain Neoplasms - therapy; Brain tumors; Chemoradiotherapy; Chemotherapy; Clinical Study; Cross-Sectional Studies; Female; Glioma; Glioma - pathology; Glioma - therapy; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Grading; Neurology; Oncology; Patients; Quality of Life; Radiation therapy; Retrospective Studies; Surgery; Temozolomide; Temozolomide - therapeutic use; Treatment Outcome; Watchful Waiting
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-021-03920-6

Purpose Low-grade glioma (LGG) exhibits longer median survival than high-grade brain tumors, and thus impact of our therapies on patient quality of life remains a crucial consideration. This study evaluated the effects of concurrent temozolomide-based chemoradiation (RT + TMZ) or observation on quality of life (QOL) in patients with low-grade glioma. Methods We completed a retrospective cross-sectional study of adults with LGG who underwent surgery with known molecular classification from 1980 to 2018. Postoperatively, patients were either observed or received adjuvant concurrent temozolomide-based chemoradiation. EQ-5D and PHQ-9 depression screen were completed before outpatient visits every 2–3 months. Baseline score was defined as ± 30 days within initial operation. Results Of the 63 patients (mean age 44 ± 17 years, 51% female) with baseline EQ-5D or PHQ-9 depression screen data and at least one follow-up measure, 30 (48%) were observed and 33 (52%) received RT + TMZ. No significant decline was seen in EQ-5D or PHQ-9 scores at 3, 6, 9, 12, and 24 months compared to baseline scores for all patients. At each time point, there was no significant difference between those who were observed or received adjuvant therapy. The linear mixed model estimating PHQ-9 value or EQ-5D index demonstrated that there was no significant difference in PHQ-9 or EQ-5D index between treatment groups (p = 0.42 and p = 0.54, respectively) or time points (p = 0.24 and p = 0.99, respectively). Conclusion Our study found no significant decline in patient QOL or depression scores as assessed by patient- reported outcome measures for patients with low-grade glioma up to 2 years following surgery. We found no difference between RT + TMZ compared to observation during this time frame. Additional follow-up can help identify the longer-term impact of treatment strategy on patient experience.